BioWorld

June 7, 2004

View Archived Issues

Myriad's Stock Sale Gets $50.2M To Move Flurizan Through Clinic

Read More

Inhibitex Gains $35M After Dropping IPO Share Price

Read More

FDA Satisfied With Rat Data; Dyax Phase II Trials Resume

Read More

SeraCare Paying $14.3M To Buy Genomics Collaborative

Read More

Other News To Note

Read More

Correction

Read More

CuraGen, TopoTarget Form HDAC Inhibitor Deal Worth Up To $100M

As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today) Read More

More Global Attendees Flock To Industry's Annual Meeting

Read More